https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1520287/full
Frontiers | Ensartinib for EML4-ALK-positive lung adenocarcinoma with comorbid mutations in TP53,...
BackgroundIn non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK) gene rearrangements are commonly detected in lung adenocarcinoma. ALK-posit...